RTI Surgical, a leading CDMO, unveils its new corporate identity as Evergen, signaling its strategic evolution into a premier Contract Development and Manufacturing Organization (CDMO) providing biosolutions in regenerative medicine. 

The new identity embodies Evergen’s commitment to innovation, quality, and patient-centered solutions in regenerative medicine. This strategic repositioning reinforces the company’s dedication to setting new industry benchmarks through customized solutions for its customers across key high-growth therapeutic areas, including cardiac, sports medicine, orthopedic surgery, neurosurgery, plastic and reconstructive surgery. 

Olivier Visa, President and Chief Executive Officer, Evergen, said: “This rebranding marks a defining moment in our Company’s evolution. Every decision we make begins with understanding patient needs and developing flexible, high-quality solutions that enable our customers to meet these needs effectively. As Evergen, we are positioned to lead a new era of regenerative medicine by becoming the trusted CDMO of choice for OEM partners.”

“Our new brand identity honors our rich heritage and unifies our employees as we become one team. As the newer businesses have integrated, it has been clear that there is a strong cultural affinity across our teams. I look forward to seeing how this further strengthens in the months and years ahead,” added Kim Spooner, Chief People Officer, Evergen.

This rebranding follows the company’s acquisition of Cook Biotech and Collagen Solutions, establishing Evergen as the industry’s only CDMO offering a comprehensive portfolio of allograft and xenograft biomaterials at scale.